Polaris Greystone Financial Group Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Polaris Greystone Financial Group reduced its stake in Eli Lilly and Co by 2.02% during the most recent quarter end. The investment management company now holds a total of 10,444 shares of Eli Lilly and Co which is valued at $863,928 after selling 215 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.Eli Lilly and Co makes up approximately 0.13% of Polaris Greystone Financial Group’s portfolio.

Other Hedge Funds, Including , Zurcher Kantonalbank (zurich Cantonalbank) reduced its stake in LLY by selling 26,855 shares or 11.61% in the most recent quarter. The Hedge Fund company now holds 204,553 shares of LLY which is valued at $16,920,624. Eli Lilly and Co makes up approx 0.22% of Zurcher Kantonalbank (zurich Cantonalbank)’s portfolio.Sanders Morris Harris reduced its stake in LLY by selling 1,193 shares or 11.61% in the most recent quarter. The Hedge Fund company now holds 9,084 shares of LLY which is valued at $757,606. Eli Lilly and Co makes up approx 0.19% of Sanders Morris Harris’s portfolio.First National Bank Of Omaha boosted its stake in LLY in the latest quarter, The investment management firm added 15,532 additional shares and now holds a total of 120,044 shares of Eli Lilly and Co which is valued at $9,637,132. Eli Lilly and Co makes up approx 0.72% of First National Bank Of Omaha’s portfolio.Tt International reduced its stake in LLY by selling 12,484 shares or 32.12% in the most recent quarter. The Hedge Fund company now holds 26,379 shares of LLY which is valued at $2,093,437. Eli Lilly and Co makes up approx 0.68% of Tt International’s portfolio.

Eli Lilly and Co opened for trading at $81.44 and hit $81.85 on the upside on Monday, eventually ending the session at $81.6, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 42,27,300 shares. Company has a market cap of $90,074 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.